Science Resources
Earth Science
Space Science
Life Science
Fields of Scientific Study
Medical Topics and Fields
Cancer Research
Nanotechnology Articles
RSS Feeds
|
 |
 |
 |
Depression is a risk factor rather than early sign of Alzheimer's disease
April 08, 2008
A new study by researchers at Rush University Medical Center supports the idea that depression is truly a risk factor for Alzheimer's disease rather than a subtle early sign of its underlying pathology. The study, published in the April issue of the Archives of General Psychiatry, found no evidence of an increase in depressive symptoms during the prodromal phase before the clinical diagnosis of Alzheimer's disease. Numerous observational studies have found higher levels of depressive symptoms in old age to be associated with increased incidence of Alzheimer's disease and mild cognitive impairment. However, previous studies have not been able to answer the question of whether depressive symptoms actually contribute to the development of dementia (risk factor hypothesis) or are a consequence of the disease (reverse causality hypothesis.)
Robert S. Wilson, PhD, a neuropsychologist at the Rush Alzheimer's Disease Center, and colleagues examined data from the Rush Religious Orders Study, a cohort of 917 older Catholic clergy without dementia at study onset, to examine the change in depressive symptoms of Alzheimer's disease before and after the emergence of the cognitive symptoms of the disease.
For up to 13 years, the study participants underwent annual clinical evaluations that included assessment of depressive symptoms, cognitive testing, and clinical classification of mild cognitive impairment (MCI) and Alzheimer's disease. During the study period, 190 participants developed Alzheimer's disease.
Consistent with earlier findings in the Rush Religious Orders Study, having more depressive symptoms at baseline was associated with increased incidence of Alzheimer's disease and MCI.
However, the study found that those who developed Alzheimer's disease showed no increase in depressive symptoms before clinical diagnosis. Researchers were able to observe patients during a mean of approximately four years before the onset of dementia. Additionally, researchers saw no increase in depression during the three to four years preceding the onset of MCI, which antedates the onset of dementia by several years.
"If depressive symptoms are a consequence of dementia or a reaction to declining function, depressive symptoms would likely increase at some point before dementia is clinically evident," said Wilson. "We observed no such increase."
The study also found that even after the diagnosis of Alzheimer's disease was made there was no general increase in depression, but rather an increase that was confined to individuals with certain personality traits.
"Depressive symptoms may be associated with distinctive changes in the brain that somehow reduce neural reserve, which is the brain's ability to tolerate the pathology associated with Alzheimer's disease," said Wilson. "Understanding how depression contributes to the development of Alzheimer's disease may suggest new approaches to disease prevention."
Rush University Medical Center
|
 |

|
Pharmacogenomics in Drug Discovery and Development (Methods in Molecular Biology)
by Qing Yan (Editor)
Since each human is genetically distinctive, responding differently to disease-causing factors as well as drugs, the field pharmacogenomics arose to develop personalized medicine, or medicine that deals with the complexity of the human body. In Pharmacogenomics in Drug Discovery and Development, leading experts present methodical, state-of-the-art contributions covering topics from individual molecules to systemic diseases, examining both fundamental concepts and advanced technologies. Divided into three sections, the volume begins by exploring cutting-edge technologies used to pursue systems-based pharmacogenomics, followed by extensive chapters on gene-drug interactions and the use of pharmacogenomics in therapeutics of diseases. Comprehensive and up-to-date, Pharmacogenomics...
|

|
New Science of Alzheimer's Disease / TIME Cover: July 17, 2000, Framed Art Print by TIME Magazine
by barewalls
The most eagerly awaited event in the editorial cycle at TIME Magazine is always the selection of the cover. The best covers capture the zeitgeist of the week while surviving the judgment of history. As browsing this collection of TIME cover art prints shows, TIME is as good a record as any of who and what mattered over the past 80-plus years. And so when TIME captures a person, an event or a trend within its iconic red borders, the magazine is adding that extra dose of significance that no other publication can quite match. That is one reason why the original artwork for more than 800 TIME covers now resides in the National Portrait Gallery in Washington. Thanks to an amazing roster of artists, photographers and graphic designers, from TIME's earliest charcoal drawings of cover subjects...
|

|
The Forgetting - A Portrait of Alzheimer's
Starring: David Hyde Pierce Directed By: Elizabeth Arledge Also With: Elizabeth Arledge (Producer), Doug Quade (Editor), Naomi S. Boak (Producer), Whitney Johnson (Producer)
Studio: Paramount Home Video Release Date: 11/01/2005
|
|
|
Alzheimer’s Disease Chart
by American 3B Scientific
Alzheimer’s Disease Chart Alzheimer’s Disease ChartThis thickly laminated anatomical chart is printed on premium glossy (200 g) UV resistant paper and comes with 2 sided lamination (125 micron, 5.0 Mil) and metal eyelets to make the chart easy to display. It comes in a convenient poster size 50 x 67 cm (20x26’’) and can be written on and wiped off with non permenant markers. The 125 micron lamination ensures the chart does not curl up at the edges and the UV treament ensures the chart does not get a faded yellow color over time.Measurements:50 x 67 cm Weight: 0,15 kgProduct photo may not exactly match the product offered for sale. Please refer to the product description.
|

|
Alzheimer's Disease: A Wilderness Exposed (NCME Video S103)
Also With: Network For Continuing Medical Education (Primary Contributor), Kenneth L. David (Primary Contributor), Allen D. Roses (Primary Contributor), Dennis J. Selkoe (Primary Contributor), Rudolph E. Tanzi (Primary Contributor)
|

|
Natrol Extra Strength ENADA NADH, 5 mg, MicroTablets - 30 ea
by Natrol
The Energizing CoEnzyme. A Patented Formula. The Only Stable NADH. Maximum Bioavailability. Dietary Supplement. Natrol® Enada®'s NADH is a patented dietary ingredient designed for those whose active lifestyles demand the very best. As a coenzyme, NADH plays a key role in the energy production of our cells and neurotransmitter processes.* Natrol offers Enada's NADH - the only stable form of NADH in the marketplace today. This exclusive patented supplement assures maximum bioavailability. *The FDA has not evaluated this statement. This product is not intended to diagnose, treat, cure or prevent disease. If you have or suspect a medical condition, consult your healthcare professional prior to use. NADH (Vegetable source) (reduced 5 nicotinamide...
|

|
A Guide to the Spiritual Dimension of Care for People With Alzheimer s Disease and Related Dementia: More Than Body, Brain, and Breath
by Eileen Shamy (Author)
In this sensitive and informative book, Eileen Shamy, a pioneer of ministry to people with Alzheimer's disease, discusses how pastoral work can help to develop holistic care for those suffering from dementia and related conditions - care which involves understanding of their spiritual as well as physical needs. From her years of experience as a clergywoman working with older people in care settings, the author provides guidelines for pastoral visits to people with dementia, showing how to empathise with, understand and support individuals during a visit. She discusses what constitutes spiritual well-being in individuals and suggests ways in which this can be nurtured. Emphasising the importance of retaining dignity and freedom of choice for people with dementia, she also presents...
|

|
The Inflammation Pathway from Cholesterol to Aging - Medications and Plants that prevent and treat Aging, Cardiovascular Disease, Osteoporosis, Arthritis, Type-2 Diabetes, Dementia and Alzheimers disease
by Sota Omoigui MD (Author)
The Inflammation Pathway has been identified after extensive research of the medical literature, as the key trigger for Aging and many disorders associated with Aging including Heart Disease, Stroke, Skin Wrinkles, Type 2 Diabetes, Dementia, Alzheimers Disease, Osteoporosis, Arthritis and certain types of Cancers. Statin drugs act on a small branch of this pathway but yet have led to a significant decrease in mortality from Heart Disease, Stroke, Type 2 Diabetes and Dementia. Statins reduce the incidence of Arthritis and certain types of Cancers and can increase bone density and treat osteoporosis by acting on this same pathway. Dr Sota Omoigui in a major breakthrough has identified the exact way that statins and bisphosphonate medications block a minor branch of this inflammatory...
|

|
Mayo Clinic on Alzheimers Disease
by M.D., Ph.D. Ronald Petersen (Editor)
|
|
|
Alzheimer's s Disease: An Overview.: An article from: Southern Medical Journal
by Ronald C. Hamdy (Author)
This digital document is an article from Southern Medical Journal, published by Southern Medical Association on July 1, 2001. The length of the article is 1102 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Alzheimer's s Disease: An Overview. Author: Ronald C. Hamdy Publication: Southern Medical Journal (Refereed) Date: July 1, 2001 Publisher: Southern Medical Association Volume: 94 Issue: 7 Page: 661
Distributed by Thomson...
|
|